Vivos Therapeutics VVOS 深 沪
等待开盘 10-28 09:30:00 美东时间
0.1283
-0.003
-2.28%
华盛通- 最 高0.1289
- 今 开0.1287
- 成交量 91.88万股
- 最 低 0.1205
- 昨 收 0.1313
- 总市值 258.11万
- 52周最高 2.72
- 市盈率 静 --
- 换手率 4.57%
- 52周最低 0.1205
- 委 比 77.78%
- 总股本 2011.80万
- 历史最高 360.25
- 量 比 0.05
- 振 幅 6.40%
- 历史最低 0.1205
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12M
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep...
10-15 20:48
Vivos Therapeutics Announces Restructuring And Cost Reduction Plan With An Annual Savings Target Of $3.6M From Q4 2026
Parts of the plan have already been implemented, with additional reductions going into effect October 1, 2026. The primary savings in the plan come from staff reductions, vendor relationship changes, negotiated contract savings, and more. The Company expects the full measure of cuts to take place in...
09-29 20:48
Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of Webuy Global Ltd (NASDAQ:WBUY) rose sharply in pre-market trading. Webuy reported record preliminary unaudited travel bookings of around $4.76 million during the three-day NATAS Fair in Aug. 2026, representing around 42% surge from the more than US$3.34 million figure announced during the ...
08-31 16:53
Vivos Opens New Henderson Sleep Testing and Treatment Center
The latest update is out from Vivos Therapeutics ( ($VVOS) ). On August 20, 202...
08-22 06:03
Vivos Therapeutics (VVOS) 2026财年第二季度业绩电话会：营收增长35%，流动性风险仍存
Vivos Therapeutics (VVOS) 2026财年第二季度业绩电话会议：随着管理层在面临流动性和Nasdaq风险之际阐述增长计划，公司营收增长35%至520万美元。
08-17 08:02
Vivos Therapeutics (VVOS) Q2 2026 Earnings Call: Revenue Up 35%, Liquidity Risks Persist
Vivos Therapeutics (VVOS) Q2 2026 earnings call: revenue rose 35% to $5.2M as management outlined growth plans amid liquidity and Nasdaq risks.
08-17 08:00
Vivos Therapeutics Q2 EPS $(0.31) Beats $(0.36) Estimate, Sales $5.153M Miss $5.367M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. This is a 43.64 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $5.153 mill...
08-15 04:16
Why Arista Networks Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of Arista Networks Inc (NYSE:ANET) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued strong third-quarter guidance. Arista Networks reported second-quarter revenue of $3.04 billion, up 37.7% year-over-year. The reven...
08-05 16:57
Vivos Therapeutics' Bradford Amman Resigns As CFO; Roman Franklin Appointed As Chief Financial Officer
Vivos Therapeutics' Bradford Amman Resigns As CFO; Roman Franklin Appointed As Chief Financial Officer
08-04 05:36
Vivos Therapeutics Announces Its Treatment With ITS FDA-Cleared Vida Oral Appliance Demonstrates Enhancement In Insomnia Severity In 100% Of Patients In Trial
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as obstructive sleep apnea (OSA), insomnia, and associated chronic health conditions, today announced compell...
06-30 20:47
